



Universiteit  
Leiden  
The Netherlands

## Pharmacist-driven interventions in patients with chronic kidney disease and end-stage renal failure

Oever, F.J. van den

### Citation



Oever, F. J. van den. (2026, March 12). *Pharmacist-driven interventions in patients with chronic kidney disease and end-stage renal failure*. Retrieved from <https://hdl.handle.net/1887/4296592>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4296592>

**Note:** To cite this publication please use the final published version (if applicable).



# CHAPTER 1

General introduction

## Section 1

### Drug stewardship in patients with chronic kidney disease (CKD) and the role of the nephrology pharmacist

Chronic kidney disease (CKD) occurs in 10 to 15% of the population worldwide and is accompanied by renal and cardiovascular complications, leading to higher mortality <sup>1,2</sup>. Renal complications increase in number and frequency when CKD progresses and include anaemia, mineral-bone disorders, hyperkalaemia, and metabolic acidosis <sup>3</sup>.

To slow disease progression and treat the renal and cardiovascular complications of CKD and comorbidities such as hypertension and diabetes, patients with CKD often use five or more different medications, which is called polypharmacy <sup>4</sup>. Polypharmacy occurs in more than 80% of the patients with CKD and around 90% of patients on haemodialysis <sup>5,6</sup>. Hyperpolypharmacy is defined as the use of at least ten different medications and occurs in 40-55% of CKD patients <sup>5,6</sup>.

Treatment of CKD is complex due to the presence of multiple comorbidities, resulting in a multitude of prescribers and hyperpolypharmacy with complex medication regimens, which pose an increased risk of suboptimal medication management <sup>7-11</sup>. Suboptimal medication management may lead to medication-related problems (MRPs).

Patients with CKD often experience multiple MRPs at a time, increasing to three to four MRPs per patient for patients on haemodialysis, leading to negative consequences such as hospitalisation <sup>12-15</sup>. Other frequent reasons for hospitalisations in patients with CKD and on haemodialysis are cardiovascular disease, infections and fluid retention <sup>11,16</sup>. The clinical pharmacist is the pre-eminent medication expert and thereby perfectly suited to guide medication management in patients with CKD, to minimise MRPs<sup>17</sup>. It is known that on-ward pharmacist interventions in patients with CKD can reduce MRPs by 45 to 85% in hospitalised patients <sup>18-21</sup>.

Although on-ward pharmacist interventions have been shown to reduce the number of MRPs, some research gaps remain. Long-term data on acceptance rate and clinical relevance of on-ward pharmacist interventions are lacking <sup>18,19,21</sup>. In studies with a follow-up of three months to one year, between 83% and 95% of

on-ward pharmacist interventions are generally accepted<sup>22-24</sup>. Clinical relevance is important for physicians' acceptance of pharmacist interventions<sup>25</sup>. However, the clinical relevance of pharmacist interventions is highly variable, with physicians assessing 30% to 56% of the interventions as clinically relevant<sup>22,23,26,27</sup>. Here too, follow-up is short with a maximum of one year.

Earlier data suggest that the acceptance rate and clinical relevance may change over time. A learning effect in both physicians and pharmacists may underlie these findings, resulting in an increase in acceptance rate and a decrease in the number of interventions during long-term participation of pharmacists in multidisciplinary ward rounds<sup>28</sup>. It is conceivable that this learning effect continues to exist for over a year, resulting in fewer but more clinically relevant pharmacist interventions with a higher acceptance rate. However, this hypothesis has not yet been confirmed in clinical studies.

Traditionally, the pharmacist's role in CKD care has mostly been reactive, consisting of advising and correcting prescribers, for example, in case of a medication overdose for a patient with reduced kidney function, or therapeutic drug monitoring for aminoglycosides and vancomycin, to optimise treatment efficacy and reduce (renal) toxicity. More recently, the pharmacist has become a more proactive member of the multidisciplinary team of healthcare professionals (HCPs) treating patients with chronic kidney disease<sup>14,18,20,29-31</sup>. In some hospitals in the Netherlands, nephrology pharmacists perform patient consultations as members of the multidisciplinary nephrology team. In CKD clinical practice in Europe, this new proactive role is gaining momentum, but it is still in the developing phase. Recent guidelines and position papers however foresee an important role for clinical pharmacists in CKD medication management and drug stewardship, which includes medication reconciliation, optimising medication impact, and reducing MRPs, for example as part of a medication review<sup>17,32</sup>.

Besides reducing MRPs in patients with CKD, nephrology pharmacists may also improve medication management. Low-quality observational studies suggest that nephrology pharmacists can improve medication management in patients with CKD and on haemodialysis. The pharmacist-managed treatment of renal anaemia with erythropoietin-stimulating agents (ESA) is an example of the contribution of nephrology pharmacists to medication management in patients with CKD.

Notwithstanding the emergence of HIF-PH(hypoxia-inducible factor prolyl-hydroxylase) inhibitors as a new treatment option, ESA are still first-line therapy in the treatment of renal anaemia<sup>33</sup>. Renal anaemia is associated with adverse outcomes, such as a higher risk of coronary artery disease, heart failure, cardiovascular hospitalisations, and mortality<sup>34–36</sup>. However, a disadvantage of long-term use of ESA is the risk of thrombotic complications, particularly major adverse cardiovascular events (MACE). MACE comprise myocardial infarction, non-haemorrhagic stroke, and cardiovascular death, the latter being the leading cause of death in patients on haemodialysis. When using ESA, higher target levels for haemoglobin are associated with an increased risk of stroke, other MACE, and worsening hypertension<sup>37–41</sup>. To reduce this risk, the current (concept) guideline recommends targeting haemoglobin levels below 7.2 mmol/L in patients with CKD and on haemodialysis<sup>33</sup>.

However, in clinical practice, it is challenging to maintain haemoglobin levels around this target level. Without the use of decision aids, only about 30% of haemodialysis patients in Europe have adequate haemoglobin values<sup>42</sup>. Several factors contribute to this finding, such as ESA hyporesponsiveness, infections, and suboptimal prescribing of ESA and iron<sup>42,43</sup>. As clinicians mainly focus on avoiding low haemoglobin levels and transfusions, high haemoglobin levels are still frequently overlooked. This leads to the erroneous continuation of (a too-high dose of) ESA, which occurs in more than a quarter of haemodialysis patients in Europe<sup>42</sup>.

Pharmacist-managed renal anaemia may improve the attainment of haemoglobin target levels. Earlier systematic reviews on pharmacist interventions included studies on pharmacist-managed renal anaemia using ESA, but had a very broad scope. Their conclusions regarding the effects of pharmacist-managed renal anaemia were ambiguous due to a lack of high-quality studies and the large heterogeneity of pharmacist interventions<sup>20,31,44</sup>. The most recent systematic review concluded that pharmacist-managed renal anaemia increased haemoglobin by 0.47 mmol/L, but it included only studies from non-Western countries, and baseline haemoglobin values were low or very low<sup>20</sup>. In Western countries nowadays, during the treatment of renal anaemia with ESA, a high haemoglobin concentration might occur more often than a low haemoglobin concentration. These high haemoglobin concentrations, especially in the case

of high ESA dose, are associated with higher rates of cardiovascular disease and mortality <sup>40,45–47</sup>. Furthermore, these systematic reviews only reported on haemoglobin outcome parameters, whereas other relevant outcome parameters, such as ESA expenditure, were missing.

To conclude, the published systematic reviews on pharmacist-managed renal anaemia using ESA reported on a broad range of interventions but lacked an in-depth discussion of pharmacist-managed renal anaemia, and their conclusions regarding pharmacist-managed anaemia were ambiguous. To provide focus on pharmacist-managed renal anaemia, incorporating a broad range of outcomes, an updated systematic review is warranted.

As stated above, there is a paucity of high-quality studies on pharmacist-managed renal anaemia using ESA, including randomised controlled trials. Therefore, more high-quality studies, preferably randomised controlled trials, investigating haemoglobin and other relevant outcome parameters, are needed to strengthen the body of evidence in this field. Furthermore, the choice of haemoglobin outcome parameter is important, as a higher haemoglobin concentration does not necessarily improve patient outcomes. Therefore, the percentage in target range for haemoglobin might be a more suitable outcome parameter than the level of haemoglobin itself.

## Section 2

### Medication self-management and adherence in patients with CKD in relation to health literacy and the pharmacist's role in improving medication adherence

Pharmacists can contribute to and improve medication management. However, the patient also has a very important role in medication management, as the greatest part of the treatment of chronic diseases, including chronic kidney disease, takes place at home. At home, the patient has to take care of managing the disease, including its symptoms, lifestyle recommendations, and medication. This is called self-management. Patients with CKD often perceive self-management as difficult and report an increase in difficulty of self-management with the progression of CKD <sup>10,48,49</sup>.

Medication self-management is part of self-management in chronic diseases in general and is defined as the range of tasks people have to undertake to successfully manage their therapeutic regimen and sustain the safe and appropriate use of medication<sup>50</sup>. As patients with CKD use approximately ten different medications<sup>5,17</sup>, medication self-management is seen as critical in this patient group<sup>38–40</sup>. Adequate medication self-management results in taking medication correctly (i.e. medication adherence), which is essential for the treatment of chronic diseases<sup>50–52</sup>.

However, suboptimal medication adherence occurs in approximately 50% of all patients with CKD<sup>53,54</sup>. Patients with CKD and on haemodialysis experience several barriers to adhering to their medication. These barriers are present in a large proportion of patients and are related to disease-specific factors such as the high prevalence of multimorbidity, hyperpolypharmacy, dietary restrictions, the large quantity of information, and the high disease burden. Other causative factors are medication-specific, such as the occurrence of side effects, a high pill burden and a complex medication regimen<sup>49,55,56</sup>. Limited health literacy skills may also impede medication adherence<sup>50,57,58</sup>.

Health literacy (HL) skills are the personal, cognitive and social skills which determine the ability of individuals to gain access to, understand, appraise, and apply health information to make well-informed health and treatment decisions<sup>59–61</sup>. Medication-related health literacy skills are essential for adequate and safe medication use. For example, patients need to be able to perform numeric tasks in understanding and using medication information with numbers, tables, graphs, and statistics<sup>62</sup>. They also need skills to recognise and respond to a lack of treatment effect as well as possible side effects. Furthermore, adequate health literacy skills are essential for patients to understand the aim of the medication, the expected treatment effects and side effects, and specific user instructions.

However, limited health literacy (HL) is present in at least 25% of patients with CKD<sup>63</sup>. Limited HL is associated with the onset of CKD, and individuals with worse renal function are more likely to have limited HL<sup>64</sup>. In most chronic diseases, limited HL is associated with reduced adherence to treatment, including adherence to medication<sup>50,52,57,58,65–71</sup>. In CKD, however, data regarding this association are conflicting, and no clear association has been found<sup>69,72–74</sup>.

To date, no studies have been published on medication-related health literacy in patients with CKD and on haemodialysis. As health literacy is content and context-specific <sup>75</sup>, it is important to investigate and describe medication-related HL (content) in the context of haemodialysis treatment.

One of the medication groups for which HL is extremely relevant is phosphate-binding medication (PBM). As the use of PBM requires a complex treatment regimen with extensive user instructions, adequate health literacy skills are needed to correctly interpret all treatment information.

PBM is used to treat a high serum phosphate concentration, one of the most common complications of CKD. Elevated serum phosphate concentrations contribute to secondary hyperparathyroidism, bone disease, and the development of atherosclerotic heart disease by inducing cardiovascular calcifications and are independently associated with a 20% to 40% increase in mortality risk among patients with end-stage renal disease (ESRD) <sup>76,77</sup>. Among PBM, sevelamer is the first-choice agent as it is associated with lower all-cause mortality <sup>78</sup>.

Besides phosphate-binding medication, diet and dialysis are used to lower serum phosphate concentrations <sup>79</sup>. However, self-management of a high serum phosphate concentration, including medication self-management of PBM, is very complex and demanding for patients. Besides dietary adjustments, taking into account the protein and phosphate content of different foods and drinks, a correct intake of phosphate-binding medication (PBM) is essential to keep the serum phosphate concentration within the target range <sup>79</sup>.

However, patients encounter several barriers to adequate intake of PBM. They consider the high pill burden and the complex pharmacotherapeutic treatment regimen with extensive user instructions to be particularly challenging. This often results in medication non-adherence, which is reported to occur in at least 50% of the patients on PBM <sup>80-83</sup>. When serum phosphate concentration remains uncontrolled, and adherence is suboptimal, this often triggers a vicious treatment circle in which the nephrologist continues to increase the PBM dose, and the patient becomes less and less satisfied with PBM treatment, with adherence diminishing further <sup>84</sup>. This may explain the finding of a higher PBM pill burden being associated with lower PBM adherence <sup>82,85</sup>.

Nephrology pharmacists are perfectly suited to guide patients in addressing barriers to adhering to PBM <sup>29,86,87</sup>. Several adherence-improving pharmacist interventions have been investigated in patients with CKD using PBM. Individualised, multi-component interventions targeting knowledge and skills mostly improved adherence to PBM and the percentage of patients within target range, but did not reduce phosphate concentrations <sup>88-92</sup>. Furthermore, the positive effects of these interventions on adherence are often short-lived, and little is known about how long the effect on adherence remains after discontinuing the intervention.

It has been suggested that a reduction in PBM pill burden might improve PBM adherence <sup>82,93</sup>. This strategy might be key to breaking the vicious treatment circle in the treatment with PBM. However, this hypothesis has not yet been tested in patients with CKD and on haemodialysis. As the most effective adherence-improving interventions are multi-component, individualised interventions <sup>88,91,92,94,95</sup>, it would be logical to combine a reduction in pill burden with addressing individual barriers to adherence to PBM.

In patients with hypertension and diabetes, a multi-component, individualised intervention addressing individual barriers to adherence has been investigated <sup>96,97</sup>. This intervention was feasible in clinical practice but did not improve self-reported medication adherence. To augment the effectiveness of the intervention, the authors recommended specifically targeting this intervention at patients with a high risk of or proven suboptimal adherence <sup>96</sup>. The combination of this multi-component, individualised pharmacist intervention with reducing PBM pill burden may be the way to go in improving adherence to PBM and thereby reducing a high serum phosphate concentration.

When an intervention has been proven effective in studies, data regarding the implementation of the intervention are often lacking. Furthermore, interventions are often poorly implemented in clinical practice, leading to suboptimal effects <sup>98</sup>. All in all, it often remains unknown how well a specific intervention was performed and what barriers and facilitators may have influenced its implementation. This lack of information impedes the effective implementation of adherence-improving interventions in clinical practice.

The implementation fidelity (IF) theory can be used to address the extent to which an intervention has been performed as designed, and what its barriers and facilitators for implementation in clinical practice are <sup>99</sup>. One framework often used for studying implementation fidelity is Carroll's Conceptual Framework for Implementation Fidelity (CFIF) <sup>99</sup>. The CFIF identifies several elements of implementation fidelity: adherence to the intervention, moderating factors, and key elements of the intervention. The IF of several pharmacist interventions has been studied using the CFIF <sup>100-103</sup>. The results of these studies show that the CFIF can help improve research on and the development and improvement of pharmacist interventions in two ways: 1) IF acts as a moderator between the intervention as designed and the effects of the intervention in research and clinical practice, which is why it is important to study it, and 2) in studying IF barriers and facilitators for the implementation of the intervention are identified, and, recommendations can be provided for the implementation of the intervention in clinical practice taking these barriers and facilitators into account.

To conclude, several research gaps remain regarding the role of the nephrology pharmacist in patients with chronic kidney disease, including those on haemodialysis, in drug stewardship and medication self-management and adherence in relation to health literacy.

## **Aim and outline of this thesis**

The overall aim of this thesis is to investigate how the interventions of a specialised nephrology pharmacist can contribute to rational, safe, and effective medication use in patients with CKD and, more specifically, in patients on haemodialysis. Health literacy and implementation fidelity will also be investigated in this thesis as they are important drivers of the effectiveness of pharmacist interventions. With the studies reported in this thesis, the position of pharmacists can be strengthened by demonstrating how the pharmacist can help to improve overall CKD outcomes as an essential member of the renal care team. The pharmacist-managed treatment of renal anaemia is discussed in Chapters 2 and 3. Chapter 2 contains the results of a systematic review of the effectiveness of pharmacist-managed and algorithm-managed renal anaemia on several outcome parameters.

In Chapter 3, a randomised controlled trial is described in which the effect of pharmacist-managed renal anaemia on haemoglobin outcomes is investigated.

Trends in acceptance rate, number, and clinical relevance of nephrology pharmacist interventions during multidisciplinary nephrology ward rounds over five years are discussed in Chapter 4.

In Chapter 5, the medication-related health literacy (HL) of haemodialysis patients using phosphate-binding medication (PBM) and its association with self-reported medication adherence is presented.

Chapters 6 and 7 contain the results of a prospective study in which we investigate a multi-component Pharmacist Intervention with Dose Optimisation of Phosphate-binding medication, the PIDO-P intervention, in haemodialysis patients with uncontrolled hyperphosphatemia and a high PBM pill burden. The goal of this intervention was to improve hyperphosphatemia. With the intervention, we address patient barriers to adherence and aim to improve adherence by reducing the pill burden. In Chapter 6, we describe the results of this intervention on phosphate concentration. Chapter 7 discusses the implementation fidelity of this intervention with a mixed methods design. Moderating factors, such as barriers and facilitators for implementation, are assessed.

In the general discussion (Chapter 8), we reflect upon the implications of the main study results and provide recommendations for clinical practice and future research.

## References

1. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *The Lancet*. 2021;398(10302):786-802. doi:10.1016/S0140-6736(21)00519-5
2. Bikbov B, Purcell C, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2020;395(10225):709-733. doi:10.1016/S0140-6736(20)30045-3
3. Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. *Kidney Int*. 2024;105(4):684-701. doi:10.1016/j.kint.2023.10.016
4. Tesfaye W, Parrish N, Sud K, Grandinetti A, Castelino R. Medication Adherence Among Patients With Kidney Disease: An Umbrella Review. *Advances in Kidney Disease and Health*. 2024;31(1):68-83. doi:10.1053/j.akdh.2023.08.003
5. Oosting IJ, Colombijn JMT, Kaasenbrood L, et al. Polypharmacy in Patients with CKD: A Systematic Review and Meta-Analysis. *Kidney360*. 2024;5(6):841-850. doi:10.34067/KID.0000000000000447
6. Van Oosten MJM, Logtenberg SJJ, Hemmelder MH, et al. Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls. *Clin Kidney J*. 2021;14(12):2497-2523. doi:10.1093/ckj/sfab120
7. Gurgel do Amaral MS, Reijneveld SA, Meems LMG, Almansa J, Navis GJ, de Winter AF. Multimorbidity prevalence and patterns and their associations with health literacy among chronic kidney disease patients. *J Nephrol*. 2022;35(6):1709-1719. doi:10.1007/s40620-021-01229-1
8. Parker K, Bull-Engelstad I, Aasebø W, et al. Medication regimen complexity and medication adherence in elderly patients with chronic kidney disease. *Hemodialysis International*. Published online 2019. doi:10.1111/hdi.12739
9. Pantuzza LL, Ceccato M das GB, Silveira MR, Junqueira LMR, Reis AMM. Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. *Eur J Clin Pharmacol*. 2017;73(11):1475-1489. doi:10.1007/s00228-017-2315-2
10. Bowling CB, Vandenberg AE, Phillips LS, McClellan WM, Johnson TM, Echt K V. Older patients' perspectives on managing complexity in CKD self-management. *Clinical Journal of the American Society of Nephrology*. 2017;12(4):635-643. doi:10.2215/CJN.06850616
11. Tonelli M, Wiebe N, Manns BJ, et al. Comparison of the Complexity of Patients Seen by Different Medical Subspecialists in a Universal Health Care System. *JAMA Netw Open*. 2018;1(7):e184852. doi:10.1001/jamanetworkopen.2018.4852

12. Pai AB, Cardone KE, Manley HJ, et al. Medication reconciliation and therapy management in dialysis-dependent patients: Need for a systematic approach. *Clinical Journal of the American Society of Nephrology*. 2013;8(11):1988-1999. doi:10.2215/CJN.01420213
13. Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related Problems in CKD. *Adv Chronic Kidney Dis*. 2010;17(5):404-412. doi:10.1053/j.ackd.2010.06.004
14. Pehlivanli A, Eyupoglu S, Basgut B, Erturk S, Ozcelikay AT. Impact of a multidisciplinary approach involving clinical pharmacist on resolving drug related problems in chronic kidney patients: a prospective interventional study. *BMC Nephrol*. 2023;24(1). doi:10.1186/s12882-023-03210-5
15. Manley HJ, Cannella CA, Bailie GR, St. Peter WL. Medication-related problems in ambulatory hemodialysis patients: A pooled analysis. *American Journal of Kidney Diseases*. 2005;46(4):669-680. doi:10.1053/j.ajkd.2005.07.001
16. Schrauben SJ, Chen HY, Lin E, et al. Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. *PLoS Med*. 2020;17(12). doi:10.1371/journal.pmed.1003470
17. Hall RK, Kazancioğlu R, Thanachayanont T, et al. Drug stewardship in chronic kidney disease to achieve effective and safe medication use. *Nat Rev Nephrol*. 2024;20(6):386-401. doi:10.1038/s41581-024-00823-3
18. Zhang S, Zhang G bing, Huang P, et al. Drug-related problems in hospitalized patients with chronic kidney diseases and clinical pharmacist interventions. *BMC Geriatr*. 2023;23(1). doi:10.1186/s12877-023-04557-y
19. Song YK, Jeong S, Han N, et al. Effectiveness of Clinical Pharmacist Service on Drug-Related Problems and Patient Outcomes for Hospitalized Patients with Chronic Kidney Disease: A Randomized Controlled Trial. *J Clin Med*. 2021;10(8). doi:10.3390/jcm10081788
20. Ardavani A, Curtis F, Hopwood E, et al. Effect of pharmacist interventions in chronic kidney disease: a meta-analysis. *Nephrol Dialysis Transpl*. Published online 2024. doi:10.1093/ndt/gfae221/7816383
21. Zafar R, Rehman IU, Shah Y, et al. Impact of pharmacist-led intervention for reducing drug-related problems and improving quality of life among chronic kidney disease patients: A randomized controlled trial. *PLoS One*. 2025;20(2 February). doi:10.1371/journal.pone.0317734
22. Yailian AL, Revel E, Tardy C, et al. Assessment of the clinical relevance of pharmacists' interventions performed during medication review in a rheumatology ward. *Eur J Intern Med*. 2019;59(June):91-96. doi:10.1016/j.ejim.2018.08.017
23. Bosma L, Jansman FGA, Franken AM, Harting JW, Van Den Bemt PMLA. Evaluation of pharmacist clinical interventions in a Dutch hospital setting. *Pharmacy World and Science*. 2008;30(1):31-38. doi:10.1007/s11096-007-9136-9

24. Sjölander M, Lindholm L, Pfister B, et al. Impact of clinical pharmacist engagement in ward teams on the number of drug-related readmissions among older patients with dementia or cognitive impairment: An economic evaluation. *Research in Social and Administrative Pharmacy*. 2019;15(3):287-291. doi:10.1016/j.sapharm.2018.05.006
25. Zaal RJ, den Haak EW, Andrinopoulou ER, van Gelder T, Vulto AG, van den Bemt PMLA. Physicians' acceptance of pharmacists' interventions in daily hospital practice. *Int J Clin Pharm*. 2020;42(1):141-149. doi:10.1007/s11096-020-00970-0
26. Bosma BE, van den Bemt PMLA, Melief PHGJ, van Bommel J, Tan SS, Hunfeld NGM. Pharmacist interventions during patient rounds in two intensive care units: Clinical and financial impact. *Netherlands Journal of Medicine*. 2018;76(3):115-124.
27. Somers A, Robays H, De Paepe P, Van Maele G, Perehudoff K, Petrovic M. Evaluation of clinical pharmacist recommendations in the geriatric ward of a Belgian university hospital. *Clin Interv Aging*. 2013;8:703-709. doi:10.2147/CIA.S42162
28. Klopotoska JE, Kuiper R, van Kan HJ, et al. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: An intervention study. *Crit Care*. 2010;14(5). doi:10.1186/cc9278
29. Calleja L, Glass BD, Cairns A, Taylor S. Pharmacist-Led Interventions for Medication Adherence in Patients with Chronic Kidney Disease: A Scoping Review. *Pharmacy*. 2023;11(6):185. doi:10.3390/pharmacy11060185
30. Alam K, Hayat AH, Ullah A, Syed Sulaiman SA, Ahmad WA, Ooi GS. The Prevalence and Impact of Clinical Pharmacists' Intervention on Drug-Related Problems in Patients With Chronic Kidney Disease. *Cureus*. Published online April 30, 2024. doi:10.7759/cureus.59402
31. Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. *Int J Clin Pharm*. 2019;41(3):630-666. doi:10.1007/s11096-019-00816-4
32. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*. 2024;105(4):S117-S314. doi:10.1016/j.kint.2023.10.018
33. KDIGO 2025 CLINICAL PRACTICE GUIDELINE FOR ANEMIA IN CHRONIC KIDNEY DISEASE (CKD): DRAFT.; 2025.
34. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. *Nephrology*. 2009;14(2):240-246. doi:10.1111/j.1440-1797.2008.01065.x
35. Lamerato L, James G, van Haalen H, et al. Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study. *BMC Nephrol*. 2022;23(1). doi:10.1186/s12882-022-02778-8

36. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J.* 2006;151(2):492-500. doi:10.1016/j.ahj.2005.03.055
37. Besarab A, Bolton W, Browne J, et al. THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN. *N Engl J Med.* 1998;339:584-590. Accessed June 25, 2017. <http://www.nejm.org/doi/pdf/10.1056/NEJM199808273390903>
38. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. *N Engl J Med.* 2006;20(16):2071-2084. [www.nejm.org](http://www.nejm.org)
39. Singh AK, Szczech L, Tang KL, et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease for the CHOIR Investigators\*. 2006;20(16). Accessed December 10, 2017. <http://www.nejm.org/doi/pdf/10.1056/NEJMoa065485>
40. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. *Lancet.* 2007;369(9559):381-388. doi:10.1016/S0140-6736(07)60194-9
41. Pfeffer MA, Burdmann EA, Chen CY, et al. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. *New England Journal of Medicine.* 2009;361(21):2019-2032. doi:10.1056/NEJMoa0907845
42. Liabeuf S, Stralen KJ Van, Caskey F, et al. Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce? *Nephrol Dial Transplant.* 2017;32(10):1737-1749. doi:10.1093/ndt/gfw409
43. Yilmaz I, Ozkok A, Kostek O, et al. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients. *Ren Fail.* 2016;38(1):89-95. doi:10.3109/0886022X.2015.1106896
44. Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacists' interventions in the management of patients with chronic kidney disease: A systematic review. *Nephrology Dialysis Transplantation.* 2012;27(1):276-292. doi:10.1093/ndt/gfr287
45. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. *Clinical Journal of the American Society of Nephrology.* 2007;2(6):1274-1282. doi:10.2215/CJN.02380607
46. Locatelli F, Aljama P, Canaud B, et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. *Nephrology Dialysis Transplantation.* 2010;25(9):2846-2850. doi:10.1093/ndt/gfq336
47. Liabeuf S, Stralen KJ Van, Caskey F, et al. Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce? *Nephrol Dial Transplant.* 2017;32(10):1737-1749. doi:10.1093/ndt/gfw409

48. Roberti J, Cummings A, Myall M, et al. Work of being an adult patient with chronic kidney disease: A systematic review of qualitative studies. *BMJ Open*. 2018;8(9). doi:10.1136/bmjopen-2018-023507
49. Escudero-Lopez M, Martinez-Andres M, Marcilla-Toribio I, Moratalla-Cebrian ML, Perez-Moreno A, Bartolome-Gutierrez R. Barriers and facilitators in self-care and management of chronic kidney disease in dialysis patients: A systematic review of qualitative studies. *J Clin Nurs*. Published online 2024. doi:10.1111/jocn.17193
50. Bailey SC, Oramasionwu CU, Wolf MS. Rethinking adherence: A health literacy-informed model of medication self-management. *J Health Commun*. 2013;18(SUPPL. 1):20-30. doi:10.1080/10810730.2013.825672
51. Lightfoot CJ, Nair D, Bennett PN, et al. Patient Activation: The Cornerstone of Effective Self-Management in Chronic Kidney Disease? *Kidney and Dialysis*. 2022;2(1):91-105. doi:10.3390/kidneydial2010012
52. van der Gaag M, Heijmans M, Spoiala C, Rademakers J. The importance of health literacy for self-management: A scoping review of reviews. *Chronic Illn*. 2022;18(2):234-254. doi:10.1177/17423953211035472
53. Cedillo-Couvert EA, Ricardo AC, Chen J, et al. Self-reported Medication Adherence and CKD Progression. *Kidney Int Rep*. 2018;3(3):645-651. doi:10.1016/j.ekir.2018.01.007
54. Hsu KL, Fink JC, Ginsberg JS, et al. Self-reported medication adherence and adverse patient safety events in CKD. *American Journal of Kidney Diseases*. 2015;66(4):621-629. doi:10.1053/j.ajkd.2015.03.026
55. Browne T, Merighi JR. Barriers to adult hemodialysis patients' self-management of oral medications. *American Journal of Kidney Diseases*. 2010;56(3):547-557. doi:10.1053/j.ajkd.2010.03.002
56. Umeukeje EM, Merighi JR, Browne T, et al. Health care providers' support of patients' autonomy, phosphate medication adherence, race and gender in end stage renal disease. *J Behav Med*. 2016;39(6):1104-1114. doi:10.1007/s10865-016-9745-7
57. Zhang NJ, Terry A, McHorney CA. Impact of Health Literacy on Medication Adherence: A Systematic Review and Meta-analysis. *Annals of Pharmacotherapy*. 2014;48(6):741-751. doi:10.1177/1060028014526562
58. Miller TA. Health literacy and adherence to medical treatment in chronic and acute illness: A meta-analysis. *Patient Educ Couns*. 2016;99(7):1079-1086. doi:10.1016/j.pec.2016.01.020
59. Koster ES, Philbert D, Bouvy ML. Health literacy among pharmacy visitors in the Netherlands. *Pharmacoepidemiol Drug Saf*. 2015;24(7):716-721. doi:10.1002/pds.3803
60. Nutbeam D. Health literacy as a public health goal: A challenge for contemporary health education and communication strategies into the 21st century. *Health Promot Int*. 2000;15(3):259-267. doi:10.1093/heapro/15.3.259
61. Sørensen K, Van Den Broucke S, Fullam J, et al. Health literacy and public health: A systematic review and integration of definitions and models. *BMC Public Health*. 2012;12(1). doi:10.1186/1471-2458-12-80

62. Schapira MM, Walker CM, Cappaert KJ, et al. The numeracy understanding in medicine instrument: A measure of health numeracy developed using item response theory. *Medical Decision Making*. 2012;32(6):851-865. doi:10.1177/0272989X12447239
63. Taylor DM, Fraser SDS, Bradley JA, et al. A systematic review of the prevalence and associations of limited health literacy in CKD. *Clinical Journal of the American Society of Nephrology*. 2017;12(7):1070-1084. doi:10.2215/CJN.12921216
64. Gurgel do Amaral MS, Reijneveld SA, Geboers B, Navis GJ, de Winter AF. Low health literacy is associated with the onset of CKD during the life course. *Journal of the American Society of Nephrology*. 2021;32(6):1436-1443. doi:10.1681/ASN.2020081155
65. Heijmans M, Waverijn G, Rademakers J, van der Vaart R, Rijken M. Functional, communicative and critical health literacy of chronic disease patients and their importance for self-management. *Patient Educ Couns*. 2015;98(1):41-48. doi:10.1016/j.pec.2014.10.006
66. Dinh TTH, Bonner A. Exploring the relationships between health literacy, social support, self-efficacy and self-management in adults with multiple chronic diseases. *BMC Health Serv Res*. 2023;23(1). doi:10.1186/s12913-023-09907-5
67. MacKey LM, Doody C, Werner EL, Fullen B. Self-management skills in chronic disease management: What role does health literacy have? *Medical Decision Making*. 2016;36(6):741-759. doi:10.1177/0272989X16638330
68. Billany RE, Thopte A, Adenwalla SF, March DS, Burton JO, Graham-Brown MPM. Associations of health literacy with self-management behaviours and health outcomes in chronic kidney disease: a systematic review. *J Nephrol*. Published online 2023. doi:10.1007/s40620-022-01537-0
69. Elisabeth Stømer U, Klopstad Wahl A, Gunnar Gøransson L, Hjorthaug Urstad K. Health Literacy in Kidney Disease: Associations with Quality of Life and Adherence. *J Ren Care*. 2020;46(2):85-94. doi:10.1111/jorc.12314
70. Coskun S, Bagcivan G. Associated factors with treatment adherence of patients diagnosed with chronic disease: Relationship with health literacy. *Applied Nursing Research*. 2021;57:151368. doi:10.1016/j.apnr.2020.151368
71. Skoumalova I, Kolarcik P, Geckova AM, et al. Is health literacy of dialyzed patients related to their adherence to dietary and fluid intake recommendations? *Int J Environ Res Public Health*. 2019;16(21). doi:10.3390/ijerph16214295
72. Yu PS, Tsai YC, Chiu YW, et al. The relationship between subtypes of health literacy and self-care behavior in chronic kidney disease. *J Pers Med*. 2021;11(6). doi:10.3390/jpm11060447
73. Wong KK, Velasquez A, Powe NR, Tuot DS. Association between health literacy and self-care behaviors among patients with chronic kidney disease. *BMC Nephrol*. 2018;19(1). doi:10.1186/s12882-018-0988-0
74. Demian MN, Jean Shapiro R, Thornton WL. An observational study of health literacy and medication adherence in adult kidney transplant recipients. *Clin Kidney J*. 2016;9(6):858-865. doi:10.1093/ckj/sfw076

75. Nutbeam D. Defining and measuring health literacy: What can we learn from literacy studies? *Int J Public Health*. 2009;54(5):303-305. doi:10.1007/s00038-009-0050-x
76. Da J, Xie X, Wolf M, et al. Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies. *American Journal of Kidney Diseases*. 2015;66(2):258-265. doi:10.1053/j.ajkd.2015.01.009
77. Hou Y, Li X, Sun L, Qu Z, Jiang L, Du Y. Phosphorus and mortality risk in end-stage renal disease: A meta-analysis. *Clinica Chimica Acta*. 2017;474:108-113. doi:10.1016/j.cca.2017.09.005
78. Hasegawa T, Nishimoto M, Murashima M, et al. Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with Chronic Kidney Disease Requiring Dialysis: A Network Meta-Analysis Full Title: Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with Chronic Kidney Disease Requiring Dialysis: A Network Meta-Analysis. *Clinical Journal of the American Society of Nephrology*. Published online 2025.
79. Rastogi A, Bhatt N, Rossetti S, Beto J. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm. *Journal of Renal Nutrition*. 2021;31(1):21-34. doi:10.1053/j.jrn.2020.02.003
80. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. *BMC Nephrol*. 2008;9(2). doi:10.1186/1471-2369-9-2
81. Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi STR. Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review. *PLoS One*. 2015;10(12):e0144119. doi:10.1371/journal.pone.0144119
82. Chiu YW, Teitelbaum I, Misra M, De Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. *Clinical Journal of the American Society of Nephrology*. 2009;4(6):1089-1096. doi:10.2215/CJN.00290109
83. Mechta Nielsen T, Marott T, Hornum M, Feldt-Rasmussen B, Kallemose T, Thomsen T. Non-adherence, medication beliefs and symptom burden among patients receiving hemodialysis -a cross-sectional study. *BMC Nephrol*. 2023;24(1). doi:10.1186/s12882-023-03371-3
84. Cozzolino M, Galassi A, Ciceri P. Phosphate binders in dialysis: better satisfied than sorry. *Clin Kidney J*. 2021;14(8):1859-1860. doi:10.1093/ckj/sfab093
85. Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking outcomes with treatment adherence. *BMC Nephrol*. 2013;14(1). doi:10.1186/1471-2369-14-153
86. Ghimire S, Banks C, Jose MD, Castelino RL, Zaidi STR. Renal pharmacists' perceptions and current practices of assessing medication adherence in dialysis patients. *Int J Clin Pharm*. 2018;40(1):26-35. doi:10.1007/s11096-017-0574-8

87. Alshogran OY, Hajjar MH, Muflih SM, Alzoubi KH. The role of clinical pharmacist in enhancing hemodialysis patients' adherence and clinical outcomes: a randomized-controlled study. *Int J Clin Pharm*. 2022;44(5):1169-1178. doi:10.1007/s11096-022-01453-0
88. Hjemås BJ, Bøvre K, Mathiesen L, Lindstrøm JC, Bjerknes K. Interventional study to improve adherence to phosphate binder treatment in dialysis patients. *BMC Nephrol*. 2019;20(1):178. doi:10.1186/s12882-019-1334-x
89. Vasli P, Hosseini M, Nasiri M, Bakhtiari N. Family-centered empowerment approach to optimize phosphate management among hemodialysis patients: an experimental study. *BMC Nephrol*. 2023;24(1). doi:10.1186/s12882-023-03311-1
90. Jasińska-Stroschein M. The Effectiveness of Pharmacist Interventions in the Management of Patient with Renal Failure: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*. 2022;19(18). doi:10.3390/ijerph191811170
91. Milazi M, Douglas C, Bonner A. A bundled phosphate control intervention (4Ds) for adults with end-stage kidney disease receiving haemodialysis: A cluster randomized controlled trial. *J Adv Nurs*. 2021;77:1345-1356. doi:10.1111/jan.14700
92. Milazi M, Bonner A, Douglas C. Effectiveness of educational or behavioral interventions on adherence to phosphate control in adults receiving hemodialysis: A systematic review. *JBI Database System Rev Implement Rep*. 2017;15(4):971-1010. doi:10.11124/JBISRI-2017-003360
93. Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. *Nephrology Dialysis Transplantation*. 2014;29(11):2092-2099. doi:10.1093/ndt/gft280
94. Umeukeje EM, Mixon AS, Cavanaugh KL. Phosphate-control adherence in hemodialysis patients: Current perspectives. *Patient Prefer Adherence*. 2018;12:1175-1191. doi:10.2147/PPA.S145648
95. Kini V, Michael Ho P. Interventions to Improve Medication Adherence: A Review. *JAMA - Journal of the American Medical Association*. 2018;320(23):2461-2473. doi:10.1001/jama.2018.19271
96. van der Laan DM, Elders PJM, Boons CCLM, Nijpels G, van Dijk L, Hugtenburg JG. Effectiveness of a Patient-Tailored, Pharmacist-Led Intervention Program to Enhance Adherence to Antihypertensive Medication: The CATI Study. *Front Pharmacol*. 2018;9. doi:10.3389/fphar.2018.01057
97. Adhien P, Van Dijk L, De Vegter M, Westein M, Nijpels G, Hugtenburg JG. Evaluation of a pilot study to influence medication adherence of patients with diabetes mellitus type-2 by the pharmacy. *Int J Clin Pharm*. 2013;35(6):1113-1119. doi:10.1007/s11096-013-9834-4
98. Keith RE, Hopp FP, Subramanian U, Wiitala W, Lowery JC. Fidelity of implementation: Development and testing of a measure. *Implementation Science*. 2010;5(1). doi:10.1186/1748-5908-5-99

99. Carroll C, Patterson M, Wood S, Booth A, Rick J, Balain S. A conceptual framework for implementation fidelity. *Implementation Science*. 2007;2(1). doi:10.1186/1748-5908-2-40
100. Willeboordse F, Schellevis FG, Meulendijk MC, Hugtenburg JG, Elders PJM. Implementation fidelity of a clinical medication review intervention: process evaluation. *Int J Clin Pharm*. 2018;40(3):550-565. doi:10.1007/s11096-018-0615-y
101. van der Laan DM, Langendoen-Gort M, Nijpels G, Boons CCLM, Elders PJM, Hugtenburg JG. Implementation fidelity of an intervention programme to enhance adherence to antihypertensive medication in Dutch community pharmacies. *Int J Clin Pharm*. 2019;41(4):1031-1046. doi:10.1007/s11096-019-00845-z
102. Batten M, Koerner J, Kosari S, Naunton M, Lewis J, Strickland K. Assessing implementation fidelity of an on-site pharmacist intervention within Australian residential aged care facilities: A mixed methods study. *BMC Health Serv Res*. 2023;23(1). doi:10.1186/s12913-023-10172-9
103. En-nasery-de Heer S, Uitvlugt EB, Bet PM, et al. Implementation of a pharmacist-led transitional pharmaceutical care programme: Process evaluation of Medication Actions to Reduce hospital admissions through a collaboration between Community and Hospital pharmacists (MARCH). *J Clin Pharm Ther*. 2022;47(7):1049-1069. doi:10.1111/jcpt.13645